SCHEMBL10089203

SCHEMBL10089203

CCN1CCN(C(=O)OCC(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 2/20 0.47
HRH1 P35367 2/20 0.47
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KIT P10721 1/20 0.43
RAB9A P51151 1/20 0.43
PIK3CD O00329 1/20 0.42
RECQL P46063 1/20 0.41
HSD11B1 P28845 1/20 0.41
TSHR P16473 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14922331 0.86 HRH2 (0.54) HRH2HRH1ALDH1A1POLBHTT
SCHEMBL5221871 0.83 RAB9A (0.43) HRH2HRH1ALDH1A1SMN1; SMN2KIT
SCHEMBL1692682 0.83 HRH2 (0.48) HRH2HRH1ALDH1A1POLBHTT
SCHEMBL8259905 0.83 ALDH1A1 (0.60) KDM4EALDH1A1POLBHTTSMN1; SMN2
SCHEMBL11392707 0.82 GAA (0.45) HRH2HRH1KDM4EALDH1A1POLB
SCHEMBL8921640 0.81 RAB9A (0.45) HRH2HRH1KDM4EALDH1A1POLB
SCHEMBL926934 0.81 HRH2 (0.42) HRH2HRH1ALDH1A1POLBHTT
SCHEMBL3958428 0.81 HRH2 (0.47) HRH2HRH1KDM4EALDH1A1HTT
SCHEMBL18482713 0.81 HRH2 (0.47) HRH2HRH1ALDH1A1POLBHTT
SCHEMBL3632495 0.81 HRH2 (0.47) HRH2HRH1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-8178509-B2 Method to treat sickle cell disease UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-05-15 US disclosed
US-8178509-B2 Method to treat sickle cell disease UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-05-15 US disclosed
US-20080027022-A1 METHOD TO TREAT GASTRIC LESIONS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2008-01-31 US disclosed
US-20080027022-A1 METHOD TO TREAT GASTRIC LESIONS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2008-01-31 US disclosed
US-20080009460-A1 METHOD TO TREAT SICKLE CELL DISEASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-01-10 US disclosed
US-20080009460-A1 METHOD TO TREAT SICKLE CELL DISEASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL HRH2 3100/4885HRH1 2094/4885KDM4E 2617/4885
US-20080009460-A1 METHOD TO TREAT SICKLE CELL DISEASE PDE4A, ADORA2A, PDE4B HRH2 1606/4885HRH1 2444/4885KDM4E 1507/4885
US-20080027022-A1 METHOD TO TREAT GASTRIC LESIONS ADORA2A, ADORA2B, PDE4A HRH2 232/4885HRH1 1027/4885KDM4E 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.